The REVEAL study is an international clinical trial that aims to find out if treating cholesterol with a new drug called anacetrapib will drive down the risk of heart attacks, deaths from heart disease and other vascular diseases.
REVEAL involves over 30,000 men and women who already have some form of circulatory disease.
Participants were recruited from over 430 hospitals and clinics in the UK, North America, China, Germany, Italy and Scandinavia.
All study participants are given atorvastatin (a commonly used "statin" drug) to ensure good control of LDL ("bad") cholesterol.
Participants also receive either anacetrapib or matching placebo (dummy) tablets daily (allocated randomly).
The primary aim of the study is to see whether fewer participants given anacetrapib have heart attacks, revascularization procedures or die from coronary heart disease than do those given the placebo tablets.
The REVEAL Collaborative Group has published a paper in the American Heart Journal, giving details of the REVEAL trial design, recruitment and baseline characteristics. You may read or download a PDF copy of the paper from:http://www.sciencedirect.com/science/article/pii/S000287031730056X
You can download the following documents in PDF format.
What is the purpose of the study?
The study is called the REVEAL trial. It is investigating whether the drug anacetrapib (a CETP inhibitor)
in combination with a statin can prevent vascular disease in high risk patients.
REVEAL is the largest study looking into the possible benefits of boosting good cholesterol and further lowering bad cholesterol to prevent heart attacks and strokes in people who have suffered these conditions before, and who are already taking statins. This means that REVEAL is uniquely positioned to answer questions about the contribution of good and bad cholesterol on the risk of serious cardiovascular diseases.
Who is running and who is funding the study?
The Clinical Trial Service Unit (CTSU) in the Nuffield Department of Population Health (NDPH) at the University of Oxford is coordinating this study and has overall responsibility for the administration and coordination of the study. There is a Steering Committee to oversee the trial conduct and an independent Data Monitoring Committee perform regular analyses on data collected so far to check that the study tablets aren't causing any illness.
Funding for this study is provided by Merck Sharp & Dohme Corp. to cover the administrative and coordination costs of the trial. The University of Oxford is acting as the sponsor of this study.^Back to FAQ
Where is the REVEAL trial registered?
The REVEAL Trial is registered with the following bodies:
• ISRCTN (International Standard Randomised Controlled Trial Number): 48678192
• ClinicalTrials.gov: NCT01252953
• EU Clinical Trials Register: 2010-023467-18
• UKCRN (UK Clinical Research Network): 10598
What happens at the Final Follow-up visit?
The final follow-up visit may take slightly longer than other visits as some additional tests and measurements are done.
Anacetrapib does not have a license currently so it will not be available once the study is completed. At the final visit all participants will be asked to stop taking the REVEAL study tablets. Participants taking the study atorvastatin will need to ask their own doctor to supply statin therapy after the final visit. The study nurses will discuss this with participants during the final visit.^Back to FAQ
If you are a REVEAL participant taking one or more of the following drugs, please contact your study nurse or doctor or ring the Freefone service on 0800 585 323 (UK) for further advice
1. For lowering cholesterol:
STATINS: if your own doctors wish to change the atorvastatin dose you are receiving in REVEAL or change to a different statin please contact your study clinic first.